FDA advisors reject accelerated approval of Biogen’s ALS drug
The FDA’s independent panel of advisors voted against endorsing accelerated approval of Biogen’s investigational ALS drug for a rare and aggressive form of the disease. The vote is not binding on the FDA, though the agency often follows the panel’s guidance. It will make a final decision on April 25. The drug tofersen was developed … Read more